{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:19:29Z","timestamp":1789676369014,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10441-2","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T10:46:02Z","timestamp":1743245162000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["FGFR3 gene mutations screening in non-muscle invasive bladder cancer (NMIBC) in the Tunisian population"],"prefix":"10.1007","volume":"52","author":[{"given":"Bilel","family":"Saidani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouha Setti","family":"Boubaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marouen","family":"Chakroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroun","family":"Ayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem","family":"Ksontini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeineb","family":"Naimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khedija","family":"Meddeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Saadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumaya","family":"Rammeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Riadh Ben","family":"Slama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"issue":"6","key":"10441_CR1","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","volume":"86","author":"P Gontero","year":"2024","unstructured":"Gontero P, Birtle A, Capoun O, Comp\u00e9rat E, Dominguez-Escrig JL, Liedberg F et al (2024) European association of urology guidelines on Non\u2013muscle-invasive bladder cancer (TaT1 and carcinoma in Situ)\u2014A summary of the 2024 guidelines update. Eur Urol 1 D\u00e9c 86(6):531\u2013549","journal-title":"Eur Urol 1 D\u00e9c"},{"issue":"3","key":"10441_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/iju.15338","volume":"31","author":"E Tomiyama","year":"2024","unstructured":"Tomiyama E, Fujita K, Hashimoto M, Uemura H, Nonomura N (2024) Urinary markers for bladder cancer diagnosis: A review of current status and future challenges. Int J Urol 1 Mars 31(3):208\u2013219","journal-title":"Int J Urol 1 Mars"},{"issue":"2","key":"10441_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.afju.2015.06.005","volume":"22","author":"M Cherif","year":"2016","unstructured":"Cherif M, Chakroun M, Bouzouita A, Dimassi H, Ayed H, Derouiche A et al (2016) Caract\u00e9ristiques \u00e9pid\u00e9miologiques du cancer de La Vessie Chez La femme En Tunisie. Afr J Urol 1 Juin 22(2):71\u201375","journal-title":"Afr J Urol 1 Juin"},{"key":"10441_CR4","doi-asserted-by":"crossref","unstructured":"Roperch JP, Hennion C (2020) A novel ultra-sensitive method for the detection of FGFR3 mutations in urine of bladder cancer patients - Design of the Urodiag\u00ae PCR kit for surveillance of patients with non-muscle-invasive bladder cancer (NMIBC). BMC Med Genet. 24 mai. 21(1):112","DOI":"10.1186\/s12881-020-01050-w"},{"key":"10441_CR5","doi-asserted-by":"crossref","unstructured":"Warrick JI, Knowles MA, Yves A, van der Kwast T, Grignon DJ, Kristiansen G et al (2020) Report From the International Society of Urological Pathology (ISUP) Consultation Conference On Molecular Pathology Of Urogenital Cancers. II. Molecular Pathology of Bladder Cancer: Progress and Challenges. Am J Surg Pathol. juill. 44(7):e30\u201346","DOI":"10.1097\/PAS.0000000000001453"},{"key":"10441_CR6","doi-asserted-by":"crossref","unstructured":"Kompier LC, Lurkin I, van der Aa MNM, van Rhijn BWG, van der Kwast TH, Zwarthoff EC (2010) FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS ONE 3(11):e13821","DOI":"10.1371\/journal.pone.0013821"},{"issue":"1","key":"10441_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Dominguez Escrig JL et al (2022) European association of urology guidelines on Non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in Situ). Eur Urol Janv 81(1):75\u201394","journal-title":"Eur Urol Janv"},{"issue":"6","key":"10441_CR8","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.canep.2010.05.003","volume":"34","author":"K Bodoor","year":"2010","unstructured":"Bodoor K, Ghabkari A, Jaradat Z, Alkhateeb A, Jaradat S, Al-Ghazo MA et al (2010) FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population. Cancer Epidemiol D\u00e9c 34(6):724\u2013732","journal-title":"Cancer Epidemiol D\u00e9c"},{"issue":"19","key":"10441_CR9","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.2217\/fon-2016-0042","volume":"12","author":"E di Martino","year":"2016","unstructured":"di Martino E, Tomlinson DC, Williams SV, Knowles MA (2016) A place for precision medicine in bladder cancer: targeting the FGFRs. Future Oncol Oct 12(19):2243\u20132263","journal-title":"Future Oncol Oct"},{"issue":"3","key":"10441_CR10","first-page":"e1130","volume":"1","author":"F Ahmad","year":"2018","unstructured":"Ahmad F, Mahal V, Verma G, Bhatia S, Das BR (2018) Molecular investigation of FGFR3 gene mutation and its correlation with clinicopathological findings in Indian bladder cancer patients. Cancer Rep (Hoboken) Oct 1(3):e1130","journal-title":"Cancer Rep (Hoboken) Oct"},{"issue":"1","key":"10441_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3233\/CBM-190483","volume":"27","author":"NS Boubaker","year":"2020","unstructured":"Boubaker NS, Gurtner A, Trabelsi N, Manni I, Said R, Ayed H et al (2020) Evaluating prognostic utility of preoperative neutrophil to lymphocyte ratio and hsa-let-7\u00a0g\/c up-regulation in patients with urinary bladder cancer. Cancer Biomark 27(1):63\u201373","journal-title":"Cancer Biomark"},{"key":"10441_CR12","first-page":"3154","volume":"35","author":"O Timonen","year":"2019","unstructured":"Timonen O, S\u00e4rkk\u00e4 M, F\u00fcl\u00f6p T, Mattsson A, Kek\u00e4l\u00e4inen J, Paananen J (2019) Varanto: variant enrichment analysis and annotation. Bioinf (Oxford England) 1 Sept 35:3154\u20133156","journal-title":"Bioinf (Oxford England) 1 Sept"},{"issue":"11 Pt C","key":"10441_CR13","first-page":"E1237","volume":"110","author":"P Korkolopoulou","year":"2012","unstructured":"Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I et al (2012) A comprehensive immunohistochemical and molecular approach to the PI3K\/AKT\/mTOR (phosphoinositide 3-kinase\/v-akt murine thymoma viral oncogene\/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. BJU Int D\u00e9c 110(11 Pt C):E1237\u20131248","journal-title":"BJU Int D\u00e9c"},{"issue":"15","key":"10441_CR14","doi-asserted-by":"publisher","first-page":"7401","DOI":"10.1158\/0008-5472.CAN-06-1182","volume":"66","author":"E L\u00f3pez-Knowles","year":"2006","unstructured":"L\u00f3pez-Knowles E, Hern\u00e1ndez S, Malats N, Kogevinas M, Lloreta J, Carrato A et al (2006) PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 1 Ao\u00fbt 66(15):7401\u20137404","journal-title":"Cancer Res 1 Ao\u00fbt"},{"key":"10441_CR15","doi-asserted-by":"crossref","unstructured":"Yu SH, Kim SS, Kim S, Lee H, Kang TW (2024) FGFR3 mutations in urothelial carcinoma: A Single-Center study using Next-Generation sequencing. J Clin Med. 13(5)","DOI":"10.3390\/jcm13051305"},{"key":"10441_CR16","doi-asserted-by":"publisher","first-page":"102530","DOI":"10.1016\/j.ctrv.2023.102530","volume":"115","author":"CM Ascione","year":"2023","unstructured":"Ascione CM, Napolitano F, Esposito D, Servetto A, Belli S, Santaniello A et al (2023) Role of FGFR3 in bladder cancer: treatment landscape and future challenges. Cancer Treat Reviews 1 Avr 115:102530","journal-title":"Cancer Treat Reviews 1 Avr"},{"issue":"4","key":"10441_CR17","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","volume":"72","author":"R Seiler","year":"2017","unstructured":"Seiler R, Ashab HAD, Erho N, van Rhijn BW, Winters B, Douglas J et al (2017) Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol 72(4):544\u2013554","journal-title":"Eur Urol"},{"key":"10441_CR18","doi-asserted-by":"crossref","unstructured":"Apolo AB, Vogelzang NJ, Theodorescu D (2015) New and promising strategies in the management of bladder cancer. Am Soc Clin Oncol Educ Book. 105\u2013112","DOI":"10.14694\/EdBook_AM.2015.35.105"},{"key":"10441_CR19","doi-asserted-by":"publisher","first-page":"429213","DOI":"10.1155\/2012\/429213","volume":"2012","author":"E di Martino","year":"2012","unstructured":"di Martino E, Tomlinson DC, Knowles MA (2012) A decade of FGF receptor research in bladder cancer: past, present, and future challenges. Adv Urol 2012:429213","journal-title":"Adv Urol"},{"issue":"41","key":"10441_CR20","doi-asserted-by":"publisher","first-page":"67435","DOI":"10.18632\/oncotarget.11883","volume":"7","author":"R Critelli","year":"2016","unstructured":"Critelli R, Fasanelli F, Oderda M, Polidoro S, Assumma MB, Viberti C et al (2016) Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up. Oncotarget 11 Oct 7(41):67435\u201367448","journal-title":"Oncotarget 11 Oct"},{"issue":"1","key":"10441_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/12615","volume":"23","author":"D Cappellen","year":"1999","unstructured":"Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X et al (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet Sept 23(1):18\u201320","journal-title":"Nat Genet Sept"},{"key":"10441_CR22","doi-asserted-by":"crossref","unstructured":"Ouerhani S, Elgaaied ABA (2012) The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer. Cancer Biomark. 2011;10(6):259\u201366","DOI":"10.3233\/CBM-2012-0254"},{"issue":"22","key":"10441_CR23","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1200\/JCO.2005.05.1771","volume":"24","author":"S Hern\u00e1ndez","year":"2006","unstructured":"Hern\u00e1ndez S, L\u00f3pez-Knowles E, Lloreta J, Kogevinas M, Amor\u00f3s A, Tard\u00f3n A et al (2006) Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 1 Ao\u00fbt 24(22):3664\u20133671","journal-title":"J Clin Oncol 1 Ao\u00fbt"},{"key":"10441_CR24","doi-asserted-by":"crossref","unstructured":"van Rhijn BWG, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms ECM et al (2003) Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol. 15 mai. 21(10):1912\u201321","DOI":"10.1200\/JCO.2003.05.073"},{"issue":"1","key":"10441_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s12672-024-01173-z","volume":"15","author":"DE Bogale","year":"2024","unstructured":"Bogale DE (2024) The roles of FGFR3 and c-MYC in urothelial bladder cancer. Discover Oncol 20 Juill 15(1):295","journal-title":"Discover Oncol 20 Juill"},{"issue":"3","key":"10441_CR26","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.3892\/ol.2017.6621","volume":"14","author":"H Kang","year":"2017","unstructured":"Kang H, Won, Kim Y, Jeong P, Park C, Kim W, Tae RD, Hee et al (2017) Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status. Oncol Lett 1 Sept 14(3):3817\u20133824","journal-title":"Oncol Lett 1 Sept"},{"issue":"4","key":"10441_CR27","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/00313020902885011","volume":"41","author":"M Karlou","year":"2009","unstructured":"Karlou M, Saetta AA, Korkolopoulou P, Levidou G, Papanastasiou P, Boltetsou E et al (2009) Activation of extracellular regulated kinases (ERK1\/2) predicts poor prognosis in urothelial bladder carcinoma and is not associated with B-Raf gene mutations. Pathology 41(4):327\u2013334","journal-title":"Pathology"},{"issue":"3","key":"10441_CR28","doi-asserted-by":"publisher","first-page":"323","DOI":"10.7150\/jca.17482","volume":"8","author":"V Weyerer","year":"2017","unstructured":"Weyerer V, Schneckenpointner R, Filbeck T, Burger M, Hofstaedter F, Wild PJ et al (2017) Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years. J Cancer 8(3):323\u2013331","journal-title":"J Cancer"},{"key":"10441_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1471-2407-11-101","volume":"11","author":"K Rouissi","year":"2011","unstructured":"Rouissi K, Bahria IB, Bougatef K, Marrakchi R, Stambouli N, Hamdi K et al (2011) The effect of tobacco, XPC, ERCC2 and ERCC5 genetic variants in bladder cancer development. BMC Cancer 22 Mars 11:101","journal-title":"BMC Cancer 22 Mars"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10441-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10441-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10441-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T16:30:27Z","timestamp":1766853027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10441-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10441"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10441-2","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"31 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective chart study involving human participants was in accordance with the ethical standards of the Ethic committee of Charles Nicolle Hospital-Tunis-Tunisia (date of approval: 16\/06\/2020) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All protocols were approved by the Charles Nicolle Ethics committee and a written informed consent form was obtained from the included patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"338"}}